Works matching AU Hao, Xuezhi

Results: 86

First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes.

Published in:

Thoracic Cancer, 2025, v. 16, n. 11, p. 1, doi. 10.1111/1759-7714.70095

By:

You, Mengxing;
Wu, Lige;
Liu, Jiayu;
Yuan, Hanqi;
Wang, Zihe;
Hao, Xuezhi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2025, v. 74, n. 7, p. 1, doi. 10.1007/s00262-025-04022-2

By:

Huang, Liling;
Zhu, Haohua;
Dai, Liyuan;
Feng, Yu;
Chen, Xinrui;
Xie, Zucheng;
Hu, Xingsheng;
Liu, Yutao;
Hao, Xuezhi;
Lin, Lin;
Wang, Hongyu;
Zhou, Shengyu;
Yao, Jiarui;
Tang, Le;
Han, Xiaohong;
Shi, Yuankai

Publication type:

Article

Long noncoding RNA HEIH depletion depresses esophageal carcinoma cell progression by upregulating microRNA-185 and downregulating KLK5.

Published in:

Cell Death & Disease, 2020, v. 11, n. 11, p. 1, doi. 10.1038/s41419-020-03170-w

By:

Wang, Bing;
Hao, Xuezhi;
Li, Xingkai;
Liang, Yicheng;
Li, Fang;
Yang, Kun;
Chen, Hengqi;
Lv, Fang;
Gao, Yushun

Publication type:

Article

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.

Published in:

2019

By:

Mu, Yuxin;
Hao, Xuezhi;
Yang, Ke;
Ma, Di;
Wang, Shouzheng;
Xu, Ziyi;
Li, Junling;
Xing, Puyuan

Publication type:

journal article

Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.

Published in:

2019

By:

Xing, Puyuan;
Wang, Shouzheng;
Wang, Qiang;
Ma, Di;
Hao, Xuezhi;
Wang, Mengzhao;
Wang, Yan;
Shan, Li;
Xin, Tao;
Liang, Li;
Liang, Hongge;
Du, Yang;
Zhang, Zhaohui;
Li, Junling

Publication type:

journal article

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02738-5

By:

Shi, Yuankai;
Chen, Jianhua;
Zhang, Helong;
Zhang, Zhihong;
Zhang, Yiping;
Wang, Zhehai;
Zhang, Shucai;
Zhao, Jian;
Liu, Chunling;
Wang, Xiuwen;
Zhao, Yanqiu;
Hu, Changlu;
Yang, Lei;
Hao, Xuezhi;
Wang, Lin;
Liu, Yunpeng;
Yu, Yan;
Zhao, Jun;
Wang, Mengzhao;
Zhang, Liangming

Publication type:

Article

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).

Published in:

BMC Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12916-022-02470-6

By:

Yang, Guangjian;
Xu, Haiyan;
Yang, Yaning;
Zhang, Shuyang;
Xu, Fei;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Hu, Xingsheng;
Liu, Yutao;
Wang, Lin;
Lin, Lin;
Wang, Zhijie;
Duan, Jianchun;
Wang, Jie;
Wang, Yan

Publication type:

Article

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.

Published in:

Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 11, p. 3081, doi. 10.1007/s00432-021-03901-2

By:

Xu, Ziyi;
Hao, Xuezhi;
Yang, Ke;
Wang, Qi;
Wang, Jing;
Lin, Lin;
Teng, Fei;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.

Published in:

Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 9, p. 2427, doi. 10.1007/s00432-020-03239-1

By:

Mu, Yuxin;
Hao, Xuezhi;
Xing, Puyuan;
Hu, Xingsheng;
Wang, Yan;
Li, Teng;
Zhang, Jinyao;
Xu, Ziyi;
Li, Junling

Publication type:

Article

Retraction Note: Long noncoding RNA HEIH depletion depresses esophageal carcinoma cell progression by upregulating microRNA-185 and downregulating KLK5.

Published in:

Cell Death & Disease, 2023, v. 14, n. 12, p. 1, doi. 10.1038/s41419-023-06365-z

By:

Wang, Bing;
Hao, Xuezhi;
Li, Xingkai;
Liang, Yicheng;
Li, Fang;
Yang, Kun;
Chen, Hengqi;
Lv, Fang;
Gao, Yushun

Publication type:

Article

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.

Published in:

2022

By:

Wang, Shasha;
Lou, Ning;
Luo, Rongrong;
Hao, Xuezhi;
Liu, Yutao;
Wang, Lin;
Shi, Yuankai;
Han, Xiaohong

Publication type:

journal article

Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review.

Published in:

BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-13155-z

By:

Lei, Siyu;
Tian, Linyan;
Yang, Lu;
Yang, Yaning;
Li, Junling;
Hu, Xingsheng;
Hao, Xuezhi;
Xu, Haiyan;
Wang, Yan

Publication type:

Article

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.

Published in:

2016

By:

Yan Sun;
Ying Cheng;
Xuezhi Hao;
Jie Wang;
Chengping Hu;
Baohui Han;
Xiaoqing Liu;
Li Zhang;
Huiping Wan;
Zhongjun Xia;
Yunpeng Liu;
Wei Li;
Mei Hou;
Helong Zhang;
Qingyu Xiu;
Yunzhong Zhu;
Jifeng Feng;
Shukui Qin;
Xiaoyan Luo;
Sun, Yan

Publication type:

journal article

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.

Published in:

Cancer Biology & Medicine, 2021, v. 18, n. 4, p. 1040, doi. 10.20892/j.issn.2095-3941.2020.0450

By:

Huihui Yin;
Lu Yang;
Gongxin Peng;
Ke Yang;
Yuling Mi;
Xingsheng Hu;
Xuezhi Hao;
Yuchen Jiao;
Xiaobing Wang;
Yan Wang

Publication type:

Article

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.

Published in:

BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10676-x

By:

Xu, Ziyi;
Hao, Xuezhi;
Wang, Qi;
Yang, Ke;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study.

Published in:

Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1145303

By:

Kailun Fei;
Gang Guo;
Jie Wang;
Zhijie Wang;
Yan Wang;
Xuezhi Hao;
Jia Zhong;
Qinxiang Guo;
Wei Guo;
Wenzhong Su;
Likun Zan;
Jiaxi Xu;
Fengwei Tan;
Xiaofei Zhuang;
Jianchun Duan

Publication type:

Article

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer.

Published in:

Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231179315

By:

Wan, Rui;
Guo, Yanrong;
Hao, Xuezhi;
Wang, Zhijie;
Duan, Jianchun;
Wang, Jie

Publication type:

Article

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study.

Published in:

Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221082339

By:

Yang, Guangjian;
Yang, Yaning;
Liu, Runze;
Li, Weihua;
Xu, Haiyan;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Zhang, Shuyang;
Ai, Xin;
Xu, Fei;
Wang, Yan

Publication type:

Article

Small cell lung cancer in the young: Characteristics, diagnosis and outcome data.

Published in:

Clinical Respiratory Journal, 2019, v. 13, n. 2, p. 98, doi. 10.1111/crj.12986

By:

Jiang, Shiyu;
Hao, Xuezhi;
Li, Junling;
Hu, Xingsheng;
Wang, Hongyu;
Wang, Yan;
Sun, Yan;
Shi, Yuankai;
Xiao, Zefen

Publication type:

Article

Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.

Published in:

Expert Review of Anticancer Therapy, 2024, v. 24, n. 3/4, p. 183, doi. 10.1080/14737140.2024.2334807

By:

Xu, Ziyi;
Li, Yan;
Wang, Lin;
Hao, Xuezhi;
Ying, Jianming;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.

Published in:

Signal Transduction & Targeted Therapy, 2022, p. 1, doi. 10.1038/s41392-021-00841-8

By:

Shi, Yuankai;
Fang, Jian;
Hao, Xuezhi;
Zhang, Shucai;
Liu, Yunpeng;
Wang, Lin;
Chen, Jianhua;
Hu, Yi;
Hang, Xiaosheng;
Li, Juan;
Liu, Chunling;
Zhang, Yiping;
Wang, Zhehai;
Hu, Yanping;
Gu, Kangsheng;
Huang, Jian'an;
Zhang, Liangming;
Shan, Jinlu;
Ouyang, Weiwei;
Zhao, Yanqiu

Publication type:

Article

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.976731

By:

Haiyan Xu;
Guangjian Yang;
Runze Liu;
Yaning Yang;
Weihua Li;
Junling Li;
Xuezhi Hao;
Puyuan Xing;
Yan Wang

Publication type:

Article

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.

Published in:

Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00603

By:

Mu, Yuxin;
Yang, Ke;
Hao, Xuezhi;
Wang, Yan;
Wang, Lin;
Liu, Yutao;
Lin, Lin;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma.

Published in:

Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00556

By:

Han, Xiaohong;
Tan, Qiaoyun;
Yang, Sheng;
Li, Junling;
Xu, Jianping;
Hao, Xuezhi;
Hu, Xingsheng;
Xing, Puyuan;
Liu, Yutao;
Lin, Lin;
Gui, Lin;
Qin, Yan;
Yang, Jianliang;
Liu, Peng;
Wang, Xingyuan;
Dai, Wumin;
Lin, Dongmei;
Lin, Hua;
Shi, Yuankai

Publication type:

Article

Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma.

Published in:

Cancer (0008543X), 2023, v. 129, n. 24, p. 3873, doi. 10.1002/cncr.34967

By:

Wang, Shouzheng;
Xie, Tongji;
Li, Yan;
Guo, Lei;
Ying, Jianming;
Wang, Yan;
Hao, Xuezhi;
Wang, Xingyuan;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Frequency control strategy of multi‐area hybrid power system based on frequency division and sliding mode algorithm.

Published in:

IET Generation, Transmission & Distribution (Wiley-Blackwell), 2019, v. 13, n. 8, p. 1145, doi. 10.1049/iet-gtd.2018.5145

By:

Mi, Yang;
He, Xingtang;
Hao, Xuezhi;
Li, Zhenkun;
Fu, Yang;
Wang, Chengshan;
Wang, Jianhui

Publication type:

Article

Sliding mode load frequency control for multiarea time-delay power system with wind power integration.

Published in:

IET Generation, Transmission & Distribution (Wiley-Blackwell), 2017, v. 11, n. 18, p. 4644, doi. 10.1049/iet-gtd.2017.0600

By:

Yang Mi;
Xuezhi Hao;
Yongjuan Liu;
Yang Fu;
Chengshan Wang;
Peng Wang;
Poh Chiang Loh

Publication type:

Article

Sliding mode load frequency control for multi‐area time‐delay power system with wind power integration.

Published in:

IET Generation, Transmission & Distribution (Wiley-Blackwell), 2017, v. 11, n. 18, p. 4644, doi. 10.1049/iet-gtd.2017.0600

By:

Mi, Yang;
Hao, Xuezhi;
Liu, Yongjuan;
Fu, Yang;
Wang, Chengshan;
Wang, Peng;
Loh, Poh Chiang

Publication type:

Article

Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas.

Published in:

Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01981-3

By:

Li, Yan;
Xie, Tongji;
Wang, Shouzheng;
Yang, Lin;
Hao, Xuezhi;
Wang, Yan;
Hu, Xingsheng;
Wang, Lin;
Li, Junling;
Ying, Jianming;
Xing, Puyuan

Publication type:

Article

Prognostic significance of CD276 in non-small cell lung cancer.

Published in:

Open Medicine, 2019, v. 14, n. 1, p. 805, doi. 10.1515/med-2019-0076

By:

Changgong Zhang;
Xuezhi Hao

Publication type:

Article

Expression of CENPE and its prognostic role in non-small cell lung cancer.

Published in:

Open Medicine, 2019, v. 14, n. 1, p. 497, doi. 10.1515/med-2019-0053

By:

Xuezhi Hao;
Tao Qu

Publication type:

Article

A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.

Published in:

Oncologist, 2020, v. 25, n. 5, p. e833, doi. 10.1634/theoncologist.2019-0391

By:

Liu, Yutao;
Hu, Xingsheng;
Jiang, Jun;
Yang, Lin;
Zhou, Shengyu;
Liu, Peng;
Li, Junling;
Wang, Yan;
Hao, Xuezhi;
Shi, Yuankai

Publication type:

Article

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China.

Published in:

Cancer Medicine, 2023, v. 12, n. 1, p. 335, doi. 10.1002/cam4.4852

By:

Yang, Guangjian;
Yang, Yaning;
Liu, Runze;
Li, Weihua;
Xu, Haiyan;
Hao, Xuezhi;
Li, Junling;
Zhang, Shuyang;
Xu, Fei;
Lei, Siyu;
Wang, Yan

Publication type:

Article

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study.

Published in:

Cancer Medicine, 2019, v. 8, n. 13, p. 5823, doi. 10.1002/cam4.2420

By:

Yang, Guangjian;
Ma, Di;
Xu, Haiyan;
Yang, Lu;
Li, Junling;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Yan

Publication type:

Article

A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.

Published in:

Cancer Medicine, 2016, v. 5, n. 6, p. 1116, doi. 10.1002/cam4.689

By:

Mo, Hongnan;
Hao, Xuezhi;
Liu, Yutao;
Wang, Lin;
Hu, Xingsheng;
Xu, Jianping;
Yang, Sheng;
Xing, Puyuan;
Shi, Youwu;
Jia, Bo;
Wang, Yan;
Li, Junling;
Wang, Hongyu;
Wang, Ziping;
Sun, Yan;
Shi, Yuankai

Publication type:

Article

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2 -Targeted Tyrosine Kinase Inhibitors.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.806737

By:

Yang, Guangjian;
Xu, Haiyan;
Hu, Jiaqi;
Liu, Runze;
Hu, Peizeng;
Yang, Yaning;
Li, Weihua;
Hao, Xuezhi;
Zhang, Shuyang;
Xu, Fei;
Ai, Xin;
Li, Junling;
Wang, Yan

Publication type:

Article

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer.

Published in:

Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.573852

By:

Hao, Xuezhi;
Shen, Aizong;
Wu, Bin

Publication type:

Article

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression.

Published in:

Cancer Management & Research, 2022, v. 14, p. 1891, doi. 10.2147/CMAR.S363446

By:

Xu, Ziyi;
Teng, Fei;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.

Published in:

Cancer Management & Research, 2022, v. 14, p. 863, doi. 10.2147/CMAR.S346173

By:

Xu, Ziyi;
Hao, Xuezhi;
Wang, Qi;
Wang, Jing;
Yang, Ke;
Wang, Shouzheng;
Teng, Fei;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study.

Published in:

Cancer Management & Research, 2019, v. 11, p. 9243, doi. 10.2147/CMAR.S221434

By:

Mu, Yuxin;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Yan;
Li, Junling

Publication type:

Article

miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer.

Published in:

Oncology Reports, 2015, v. 34, n. 6, p. 3088, doi. 10.3892/or.2015.4301

By:

LIN LIN;
HAIBO LIN;
LIN WANG;
BIN WANG;
XUEZHI HAO;
YUANKAI SHI

Publication type:

Article

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.

Published in:

Community Practitioner, 2021, v. 94, n. 6, p. 1040, doi. 10.20892/j.issn.2095-3941.2020.0450

By:

Huihui Yin;
Lu Yang;
Gongxin Peng;
Ke Yang;
Yuling Mi;
Xingsheng Hu;
Xuezhi Hao;
Yuchen Jiao;
Xiaobing Wang;
Yan Wang

Publication type:

Article

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice.

Published in:

Thoracic Cancer, 2022, v. 13, n. 23, p. 3295, doi. 10.1111/1759-7714.14684

By:

Yang, Yaning;
Ai, Xin;
Xu, Haiyan;
Yang, Guangjian;
Yang, Lu;
Hao, Xuezhi;
Yang, Ke;
Mi, Yuling;
Wang, Guizhen;
Zhang, Shuyang;
Lei, Siyu;
Wang, Yan

Publication type:

Article

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences.

Published in:

Thoracic Cancer, 2022, v. 13, n. 22, p. 3105, doi. 10.1111/1759-7714.14659

By:

Xu, Fei;
Chen, Heng‐chi;
Xu, Haiyan;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Ying, Jianming;
Wang, Yan

Publication type:

Article

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.

Published in:

Thoracic Cancer, 2022, v. 13, n. 1, p. 107, doi. 10.1111/1759-7714.14232

By:

Zou, Zihua;
Hao, Xuezhi;
Zhang, Cuiying;
Li, Haojing;
Dong, Guilan;
Peng, Yumei;
Ma, Kewei;
Guo, Ye;
Shan, Li;
Zhang, Yan;
Liang, Li;
Gu, Yangchun;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Published in:

Thoracic Cancer, 2021, v. 12, n. 21, p. 2924, doi. 10.1111/1759-7714.14156

By:

Li, Teng;
Wang, Shouzheng;
Ying, Jianming;
Wang, Yan;
Hu, Xingsheng;
Hao, Xuezhi;
Xu, Ziyi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.

Published in:

Thoracic Cancer, 2021, v. 12, n. 19, p. 2585, doi. 10.1111/1759-7714.14144

By:

Wang, Shouzheng;
Xie, Tongji;
Hao, Xuezhi;
Wang, Yan;
Hu, Xingsheng;
Wang, Lin;
Li, Yan;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC).

Published in:

Thoracic Cancer, 2021, v. 12, n. 17, p. 2360, doi. 10.1111/1759-7714.14078

By:

Xu, Ziyi;
Li, Teng;
Hu, Xingsheng;
Hao, Xuezhi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

Published in:

Thoracic Cancer, 2021, v. 12, n. 16, p. 2233, doi. 10.1111/1759-7714.14057

By:

Xu, Ziyi;
Hao, Xuezhi;
Lin, Lin;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs.

Published in:

Thoracic Cancer, 2020, v. 11, n. 12, p. 3501, doi. 10.1111/1759-7714.13689

By:

Yang, Lu;
Hao, Xuezhi;
Hu, Xingsheng;
Wang, Zhijie;
Yang, Ke;
Mi, Yuling;
Yang, Yaning;
Xu, Haiyan;
Yang, Guangjian;
Wang, Yan

Publication type:

Article